HNPOLY(300630)

Search documents
普利制药:2023年半年度募集资金存放与使用情况的专项报告
2023-08-24 10:41
| 证券代码:300630 | 证券简称:普利制药 | 公告编号:2023-099 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 海南普利制药股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等有关规定,海南普利制药股份有限公司(以下简 称"公司")董事会编制了 2023 年半年度募集资金存放与使用情况的专项报告, 专项报告具体情况如下: 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意海南普利制药股份有限公司向不特 定对象发行可转换公司债券注册的批复》(证监许可〔2021〕106 号),公司由主 承销商海通证券股份有限公司向不特定对象发行可转换公司债券 850 万张,每张 面值为人民币 100 元。本次发行的募集资金总额 ...
普利制药:关于注射用比伐芦定获得澳大利亚药物管理局(TGA)上市许可的公告
2023-08-15 07:46
| 证券代码:300630 | 证券简称:普利制药 | 公告编号:2023-095 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 海南普利制药股份有限公司 (一)药品名称:注射用比伐芦定 (二)适应症:适用于接受经皮冠状动脉介入术(PCI)的成人患者,包括 ST 段抬高型心肌梗死(STEMI)患者的治疗。适用于计划紧急或早期干预的不 稳定型心绞痛/非 ST 段抬高型心肌梗死(UA/NSTEMI)成人患者的治疗。 (三)剂型:注射剂 (四)规格:250 mg (五)生产厂家:海南普利制药股份有限公司 二、药品的其他相关情况 关于注射用比伐芦定获得澳大利亚药物管理局(TGA) 上市许可的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 海南普利制药股份有限公司(以下简称"普利制药"或"公司")于近日收到了 澳大利亚药物管理局(TGA)签发的注射用比伐芦定的上市许可,现将相关情况 公告如下: 一、药品基本情况 2020 年 6 月获得了德国联邦药物和医疗器械管理局(BfArM)的批准;于 2020 年 9 ...
普利制药:普利制药业绩说明会、路演活动等
2023-05-29 10:26
证券代码: 300630 证券简称:普利制药 海南普利制药股份有限公司 投资者关系活动记录表 编号:2023-004 4、汇率变化对公司利润有影响吗? 尊敬的投资者,您好。汇率的波动对公司暂时未产生重大影 响,谢谢。 5、请问公司 β-烟酰胺单核苷酸产品的应用领域? 尊敬的投资者,您好。β-烟酰胺单核苷酸产品主要应用于 抗衰保健食品和医学药物,例如 DNA 修复、解酒护肝、抗衰老、 保护视力、防治糖尿病等。目前公司 β-烟酰胺单核苷酸产品已 经完成了酶催化技术路线的开发,以葡萄糖为底物的全发酵路线 正在开发中,谢谢。 6、请问公司今年国内市场主要驱动力在哪? 投资者关系活动 类别 □特定对象调研 □ 分析师会议 □ 媒体采访 √业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称及 人员姓名 投资者网上提问 时间 2023 年 5 月 26 日 (周五) 下午 14:30~17:00 地点 公司通过全景网"投资者关系互动平台"(https://ir.p5w.net) 采用网络远程的方式召开业绩说明会 上市公司接待人 员姓名 1、董事会秘书周茂 2、财务总监罗佟凝 3、证券事务代表吴世 ...
普利制药:关于参加2022年度海南辖区上市公司业绩说明会的公告
2023-05-18 11:11
| 证券代码:300630 | 证券简称:普利制药 | 公告编号:2023-062 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 海南普利制药股份有限公司 关于参加"2022 年度海南辖区上市公司业绩说明会"的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制,让投资者 更准确地读懂年度报告、更全面地了解上市公司,切实提高上市公司透明度和治 理水平,海南普利制药股份有限公司(以下简称"公司")将参加由海南证监局 与深圳市全景网络有限公司、海南上市公司协会联合举办"海南辖区投资者网上 集体接待日暨上市公司业绩说明会"活动,活动时间为 2023 年 5 月 26 日 14:30-17:00,平台登陆地址为:http://rs.p5w.net。 届时,公司主要高管人员将参加本次活动,通过网络在线交流形式,就公司 2022 年年报披露、财务数据、公司治理、内部控制、发展战略、经营状况、现 金分红、重大事项、可持续发展等投资者所关心的问题,与投资者进行" ...
普利制药(300630) - 2023 Q1 - 季度财报
2023-04-24 16:00
Financial Performance - The company's revenue for Q1 2023 was CNY 373,166,292.20, representing a 1.42% increase compared to CNY 367,925,505.63 in the same period last year[13] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[13] - The total comprehensive income for the first quarter of 2023 was approximately CNY 138.43 million, a decrease from CNY 161.78 million in the same period last year, representing a decline of about 14.4%[43] - Basic and diluted earnings per share for the first quarter were CNY 0.32, down from CNY 0.37 in the previous year, indicating a decrease of approximately 13.5%[43] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the previous year[13] - Cash inflow from operating activities totaled CNY 446.38 million, an increase of 24.8% compared to CNY 357.66 million in the same period last year[43] - Cash outflow from operating activities was CNY 417.60 million, up from CNY 335.38 million, resulting in a net cash flow from operating activities of CNY 28.78 million, an increase of 29.5% year-over-year[43] - The company's cash flow statement indicates a stable cash position, with no significant changes reported in cash flow from operating activities[26] - The ending balance of cash and cash equivalents was CNY 530.38 million, compared to CNY 470.60 million at the end of the previous year, reflecting a decrease in cash reserves[45] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 6,199,028,028.60, a 25.50% increase from CNY 4,939,389,761.87 at the end of the previous year[13] - The company's cash and cash equivalents decreased to CNY 558,387,952.23 from CNY 777,248,693.86[19] - Accounts receivable increased to CNY 1,014,589,461.88 from CNY 924,070,859.41, indicating a growth of approximately 9.7%[19] - Current liabilities decreased to CNY 1,248,308,071.79 from CNY 1,484,098,044.10, a reduction of approximately 15.9%[22] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96, representing a growth of about 45%[22] - The total liabilities rose to ¥3,258,533,476.71 from ¥3,156,510,196.83, an increase of approximately 3.23%[36] Investment and Expenses - The company reported a significant increase in investment income, rising by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[16] - Research and development expenses amounted to ¥61,517,923.07, compared to ¥56,659,055.19 in the previous period, indicating an increase of about 8.25%[24] - Total operating costs increased to ¥243,515,781.30 from ¥212,061,775.12, marking a rise of about 14.85%[24] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,586[16] - The company has a total of 113,674,906 shares, with 25% of these shares subject to a lock-up period[18] - The total equity attributable to shareholders increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, reflecting a growth of about 4.93%[36]
普利制药(300630) - 2023 Q1 - 季度财报
2023-04-24 16:00
Financial Performance - The company's operating revenue for Q1 2023 was CNY 373,166,292.20, an increase of 1.42% compared to CNY 367,925,505.63 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 128,887,445.84, down 13.28% from CNY 148,627,173.03 in the previous year[5] - Total operating revenue for the current period reached ¥373,166,292.20, an increase from ¥367,925,505.63 in the previous period, representing a growth of approximately 0.66%[32] - Net profit for the current period was ¥138,433,086.41, down from ¥161,777,968.14, indicating a decrease of approximately 14.39%[34] - The total comprehensive income attributable to the parent company's owners was approximately $138.43 million, down from $161.78 million in the previous period, representing a decrease of about 14.4%[49] - Basic and diluted earnings per share were both $0.32, compared to $0.37 in the previous period, reflecting a decline of approximately 13.5%[49] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the same period last year[5] - Cash inflow from operating activities totaled approximately $446.38 million, an increase of about 25% from $357.66 million in the previous period[49] - Cash outflow from operating activities was approximately $417.60 million, up from $335.38 million, indicating an increase of about 24.5%[49] - The net cash flow from operating activities was approximately $28.78 million, an increase of about 29.5% compared to $22.28 million in the previous period[49] - Cash outflow from investing activities was approximately $380.89 million, compared to $319.84 million in the previous period, representing an increase of about 19.1%[52] - The net cash flow from investing activities was negative at approximately $380.89 million, worsening from a negative $215.46 million in the previous period[52] - Cash inflow from financing activities was approximately $416.41 million, down from $448.28 million, indicating a decrease of about 7.1%[52] - The net cash flow from financing activities was approximately $137.24 million, a decrease of about 38.9% from $224.92 million in the previous period[52] - The ending cash and cash equivalents balance was approximately $530.38 million, compared to $470.60 million in the previous period, reflecting an increase of about 12.7%[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,199,028,028.60, reflecting a growth of 4.03% from CNY 5,959,020,827.97 at the end of the previous year[5] - Total current liabilities were CNY 1,248,308,071.79, compared to CNY 1,484,098,044.10 previously[30] - The total liabilities increased to ¥3,258,533,476.71 from ¥3,156,510,196.83, showing a growth of approximately 3.23%[45] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96[30] - The company's short-term borrowings decreased to CNY 484,841,770.00 from CNY 613,389,696.81[30] Equity and Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.92% to CNY 2,940,494,551.89 from CNY 2,802,510,631.14 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, representing a growth of about 4.93%[45] - The company has a total of 31,026,544 shares held by its largest shareholder, Zhu Xiaoping[24] Expenses and Income - The company's inventory increased by 50.53% to CNY 485,459,996.95, up from CNY 322,510,850.58, indicating an increase in production stock[23] - The company's financial expenses decreased by 51.06% to CNY 8,759,306.14 from CNY 17,898,376.80, due to the capitalization of interest expenses[23] - The company received government subsidies amounting to CNY 9,070,325.65, a decrease of 30.31% compared to CNY 13,015,588.30 in the previous year[23] - The company reported an increase in investment income by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[23] - Research and development expenses rose to ¥61,517,923.07 from ¥56,659,055.19, reflecting an increase of about 8.73%[32] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[34] - The company reported a financial asset impairment loss of ¥-1,694,678.65, compared to ¥-1,250,138.89 in the previous period[34] - Other income decreased to ¥9,070,325.65 from ¥13,015,588.30, indicating a decline of about 30.38%[32]
普利制药(300630) - 2022 Q4 - 年度财报
2023-04-24 16:00
Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year increase of 15%[192]. - The net profit for the year was RMB 300 million, which is a 20% increase compared to the previous year[192]. - The company has set a revenue guidance of RMB 1.5 billion for the next fiscal year, indicating an expected growth of 25%[192]. - New product launches are expected to contribute an additional RMB 200 million in revenue in 2023[192]. - Cash flow from operating activities increased due to higher sales collections, indicating improved liquidity[69]. - The company's cash and cash equivalents at the end of 2022 were ¥777,248,693.86, representing 13.04% of total assets, up from 9.49% at the beginning of the year[71]. - The total sales revenue from major drug products accounted for over 10% of its main business income during the reporting period[31]. - The total sales amount of the top five customers is 596,766,787.57 yuan, accounting for 33.04% of the annual total sales[88]. Research and Development - The company is committed to continuous research and development, with plans to invest significantly in innovative drug formulations and technologies to maintain competitive advantage[20]. - The company has established two innovative drug research institutions focusing on BNCT and mRNA fields, with plans to enter the preclinical stage for early development projects by late 2023[28]. - The company has a strong R&D team of 550 people, which accounts for over one-third of its total workforce of 1,520 employees[40]. - Research and development expenses increased by 14.70% to approximately ¥263 million in 2022, reflecting the company's commitment to enhancing its R&D capabilities[54]. - The number of R&D personnel rose by 20.88% to 550 in 2022, with a notable increase in the number of master's degree holders by 37.58%[55]. - The company is actively pursuing collaborations with universities and research institutions to enhance its drug development capabilities[38]. - The company is developing a new high-efficiency pancreatic cancer treatment drug, currently in preclinical research, with pharmacology and GLP-level toxicity tests completed[55]. Product Development and Market Expansion - The company has developed new products, including a unique formulation of Diclofenac Sodium sustained-release capsules and a dry suspension for Trimebutine Maleate, which are expected to contribute to future revenue growth[24]. - The company is focused on expanding its market presence through strategic partnerships and collaborations, aiming to increase its share in both domestic and international markets[21]. - The company is actively expanding its product pipeline in the international innovative drug sector, focusing on boron drugs for cancer treatment, with ongoing collaborations with the Chinese Academy of Sciences and Zhejiang University[104]. - The company is enhancing its sales management by shifting from monthly to weekly management and optimizing its professional sales team to improve market penetration[107]. - The company is focusing on international market expansion, particularly in Europe and other countries, where its approved products have limited presence, indicating substantial growth potential[105]. - The company has signed significant sales and procurement contracts, with performance as of the reporting period being satisfactory[49]. Compliance and Governance - The company maintains a complete and independent governance structure, ensuring compliance with relevant laws and regulations, with no significant discrepancies in governance practices[118]. - The company has established an audit committee responsible for internal and external audit communication and supervision[162]. - The company has engaged in extensive communication with investors regarding its operational strategies and performance, ensuring no undisclosed major information leaks occurred[111]. - The remuneration structure for directors and senior management is based on performance evaluations conducted by the compensation committee[176]. - The company has appointed independent directors with extensive experience in law and finance, strengthening its governance structure[150]. Strategic Investments and Financial Management - The company plans to utilize the remaining unspent funds from its convertible bond issuance for project construction and liquidity support[77]. - The total investment amount during the reporting period is 740,379,635.66 yuan, representing an increase of 8.40% compared to the previous year's investment of 682,978,170.86 yuan[97]. - The company has made strategic investments in two subsidiaries, with a total investment of ¥15 million, acquiring 100% ownership in both[51]. - The company has a robust investor relations management system, ensuring timely and accurate information disclosure to all shareholders[116]. - The company reported a total investment of 137,781.37 million in committed projects, with 110,718.51 million actually invested by the end of the reporting period, achieving 80.4% of the planned investment[123]. Product Quality and Compliance - The company emphasizes adherence to GMP standards to ensure product quality and compliance with regulatory requirements[197]. - The company has received multiple certifications from international regulatory bodies, including the FDA and WHO, for various injectable products, indicating compliance with global quality standards[26]. - The company has received multiple GMP certifications for various products, including raw materials and dosage forms, from regulatory authorities in Hainan and Zhejiang provinces[33][34]. Future Outlook - The company anticipates a positive outlook for the next fiscal year, projecting a revenue growth rate of approximately 15% driven by new product launches and increased market demand[25]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[192]. - Multiple new products are expected to be approved in 2023 across the US, Netherlands, UK, Germany, and Canada, contributing to sustained sales growth, particularly from two newly approved contrast agents[105].
普利制药:关于举行2022年度网上业绩说明会的公告
2023-04-24 11:31
关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码:300630 | 证券简称:普利制药 | 公告编号:2023-040 | | --- | --- | --- | | 债券代码:123099 | 债券简称:普利转债 | | 海南普利制药股份有限公司 投 资 者 可 于 2023 年 5 月 10 日 ( 星 期 三 ) 15 : 00 前访问 海南普利制药股份有限公司(以下简称"公司")的《2022 年年度报告全文 及摘要》于 2023 年 4 月 25 日刊登在中国证监会创业板指定信息披露网站巨潮资 讯(http://www.cninfo.com.cn)。为了更好地与广大投资者进行交流,使投资 者能够进一步了解公司的经营状况、财务状况及未来发展规划等,公司拟举行 2022 年度业绩说明会。 一、活动时间 公司将于 2023 年 5 月 10 日(星期三)15:00-17:00 举行 2022 年度网上业 绩说明会。 二、活动方式 本次年度业绩说明会将采用网络远程的方式举行,投资者可在上述时间登陆 全景 ...
普利制药(300630) - 2017年4月18日投资者关系活动记录表
2022-12-06 05:08
投资者关系活动记录表 证券代码:300630 证券简称:普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号:2017-001 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 (请文字说明其他活动内容) | | 参与单位名称及 | | 上投摩根基金管理有限公司 叶敏 方钰涵 | | 人员姓名 | | 鹏华基金管理有限公司 段涛 桑翔宇 | | | 富国基金管理有限公司 姜恩铸 | | | | 长城基金管理有限公司 朱玮琳 | | | | 大成基金管理有限公司 邹建 | | | | 中海基金管理有限公司 郑磊 | | | | | 景顺长城基金管理有限公司 余捷涛 | | | 泰康资产管理有限责任公司 郑宁 | | ...